ACO Does Worse Than Either Disease Alone
November 19, 2026

A clinical brief for referring providers — week 4 of a 4-part series on asthma-COPD overlap.
A question before the clinical note: Which statement best reflects the current evidence base for asthma-COPD overlap?
a) A single international consensus definition is now widely accepted b) ACO patients were well represented in the major asthma and COPD RCTs c) Blood eosinophils reliably distinguish ACO from asthma and COPD d) Most treatment recommendations are extrapolated because ACO patients were excluded from trials e) Biologic efficacy in well-phenotyped ACO populations has been firmly established
ACO generally carries a worse prognosis than asthma or COPD alone, and it sits in one of the least evidence-based areas of airways disease. Those two facts together are the case for close monitoring.
What worse looks like
Greater symptom burden and worse health-related quality of life
More frequent and more severe exacerbations and hospitalizations
Greater lung function decline and reduced life expectancy compared with COPD alone (GOLD 2026)
Higher healthcare utilization and cost
Frequent multimorbidity — depression, metabolic and cardiovascular disease
Mucus plugging is the prognostic red flag. It is more common in asthma and ACO than in COPD alone, and its extent is associated with increased mortality.
What to monitor
Lung function — Serial spirometry, tracking persistent airflow limitation and the rate of FEV1 decline
Biomarkers — Blood eosinophils and FeNO, to guide ICS and biologic decisions
Control — ACT or CAT, and exacerbation frequency
ICS safety — Pneumonia risk in COPD-predominant patients; osteoporosis
Every visit — Inhaler technique and adherence
When to send them to us
Exacerbations that persist on triple therapy. A phenotype you cannot settle. A biologic decision on the table. Extensive mucus plugging on CT.
Your patient gets a full pulmonary evaluation: the diagnosis worked up, the phenotype defined, treatable traits matched to therapy, and a monitoring plan. You get our assessment, and your patient comes back to you with a plan to follow.
Refer your toughest overlap patient
Pulmonary evaluation with the Chest & Sleep Team. Tell us what you are seeing and we will take it from there.
Call (847) 860-7250.
Sources: GINA 2026; GOLD 2026; Leung & Sin, Chest 2022; Mekov et al., Int J COPD 2021.
Abbreviations: ACO, asthma-COPD overlap. RCT, randomized controlled trial. FEV1, air forced out in the first second. FeNO, fractional exhaled nitric oxide. ICS, inhaled corticosteroid. ACT, Asthma Control Test. CAT, COPD Assessment Test.
The answer
Most recommendations are extrapolated. There is no consensus definition, biomarkers overlap across diagnoses, ACO patients were largely excluded from trials, and biologic use rests on severe-asthma and eosinophilic-COPD data.
